Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
Mycoses
; 63(6): 604-609, 2020 Jun.
Article
em En
| MEDLINE
| ID: mdl-32246512
ABSTRACT
BACKGROUND:
To date, there are few studies that describe pharmacokinetics, safety and efficacy of posaconazole delayed-release tablet (DRT) formulation in the paediatric population.OBJECTIVES:
We evaluated retrospectively posaconazole plasma concentrations and safety of posaconazole DRT in paediatric haematology-oncology patients. PATIENTS ANDMETHODS:
Posaconazole DRT was assessed in 28 haematological paediatric patients with a median age 15 of years (range 5-18) and a median body weight of 50 kg (range 22-83 kg). Twenty-one patients received posaconazole DRT as prophylaxis and 7 patients as therapy.RESULTS:
As prophylaxis, the median daily dose was 5.5 mg/kg/day (range 2.2-22.2) with posaconazole trough level ≥ 0.7 µg/mL in 80% by first week, 62.5% by second week and 87.5% by fourth week. As therapy, the median daily dose was 4 mg/kg/day (range 3.3-4.5) with trough level ≥ 1 µg/mL 100% by first week, 80% by second week and 33.4% by fourth week.CONCLUSIONS:
Posaconazole DRT is feasible in paediatric patients capable to swallow tablets. Specific pharmacokinetic studies are needed.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Triazóis
/
Neoplasias Hematológicas
/
Micoses
/
Antifúngicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália